Stephen John Oliver - NIBR Translat Med, Novartis Pharma AG

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 11 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial

Marianna Rowlands,Thomas Doerner, Diego Saldana Miranda, Justin McMullen,Aida Santos da Costa,Ulrike Sommer,Rainer Hillenbrand, Andre Nogueira da Costa, Claire Bonal, Isabelle Isnardi, Edward Khokhlovich,Stephen J. Oliver

ARTHRITIS & RHEUMATOLOGY (2024): 4918-4920

Cited0Views0Bibtex

P41 Assessment of Cognitive Function in a Randomized, Placebo-Controlled, Interventional Trial Conducted in Patients with Moderate-to-severe Systemic Lupus Erythematosus (SLE)

Tirtha Sengupta,Carole Sips,Alexandre Avrameas, Evan D Remington,Jelena Curcic,Kristin Hannesdottir,Valeria De Luca,Stephen J Oliver

Poster presentations (2024)

Cited0Views0Bibtex

Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for Up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study

Eduardo Mysler, Stanislav Ignatenko, Alexander Gordienko,Josefina Cortes-Hernandez,Nancy Agmon-Levin,Pongthorn Narongroeknawin,Katarzyna Romanowska-Prochnicka,Nan Shen,Hana Ciferska,Masanari Kodera,James Cheng-Chung Wei,Piotr Leszczynski,Joung Liang Lan,Rafal Wojciechowski,Tunde Tarr, Elena Vishneva,Yi-Hsing Chen,Yuko Kaneko,Stephanie Finzel,Alberta Hoi,Masato Okada,Ajchara Koolvisoot,Shin-Seok Lee,Lie Dai,Hiroshi Kaneko,Bernadette Rojkovich,Lingyun Sun, Eugeny Zotkin,Jean-Francois Viallard, Berta Paula Magallares,Tirtha Sengupta,Carole Sips, Carole Lau,Alexandre Avrameas,Stephen J. Oliver

ARTHRITIS & RHEUMATOLOGY (2024): 5238-5240

Cited0Views0Bibtex

Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR Mab) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity

Nan Shen, Stanislav Ignatenko, Alexander Gordienko,Josefina Cortes Hernandez,Nancy Agmon-Levin,Pongthorn Narongroeknawin,Katarzyna Romanowska-Prochnicka,Hana Ciferska,Masanari Kodera,James Cheng-Chung Wei,Piotr Leszczynski,Joung-Liang Lan,Eduardo Mysler,Rafal Wojciechowski,Tunde Tarr, Elena Vishneva,Yi-Hsing Chen,Yuko Kaneko,Stephanie Finzel,Alberta Hoi,Ajchara Koolvisoot,Shin-Seok Lee,Lie Dai,Hiroshi Kaneko,Bernadette Rojkovich,Lingyun Sun, Eugeny Zotkin,Jean-Francois Viallard,Masao Katayama, Berta Paula Magallares-Lopez,Tirtha Sengupta, Carol Sips,Stephen J. Oliver

ARTHRITIS & RHEUMATOLOGY (2023): 4936-4939

Cited0Views0Bibtex

Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial

Aida Santos da Costa,Thomas Doerner,Andrea Grioni,Alexandre Avrameas,Ulrike Sommer,Rainer Hillenbrand,Valeria De Luca,Enrico Ferrero, Andre Nogueira da Costa, Isabelle Isnardi,Stephen J. Oliver

ARTHRITIS & RHEUMATOLOGY (2023): 4643-4645

Cited0Views0Bibtex

Ianalumab (VAY736) in Primary Sjögren's Syndrome: Assessing Disease Activity Using Multi-Modal Ultrasound

T. Diekhoff,T. Fischer,Q. Schefer,M. G. Posch,T. Doerner,D. Laurent,Y. Li,F. D. Wagner,S. J. Oliver

Clinical and Experimental Rheumatology（2020）

Cited6Views0WOSBibtex

Treatment of Primary Sjögren’s Syndrome with Ianalumab (VAY736) Targeting B Cells by BAFF Receptor Blockade Coupled with Enhanced, Antibody-Dependent Cellular Cytotoxicity

Thomas Doerner, Maximilian Georg Posch,Yue Li,Olivier Petricoul,Maciej Cabanski, Julie Marie Milojevic, Esther Kamphausen,Marie-Anne Valentin, Claudia Simonett,Louise Mooney,Andreas Hueser,Hermann Gram,Frank Dietrich Wagner,Stephen John Oliver

Annals of the Rheumatic Diseases（2019）

Cited138Views0WOSBibtex

138

AB0632 Essdai Domain Evaluation of Primary Sjögren’s Syndrome (PSS) Patients Enrolled in Two Independent Poc Studies Indicates Differential Utility of Domains for Trial Inclusion and Composite Endpoints in Pss Trials

T. Dörner,B.A. Fisher,X. Ren,P. Faerber,P. Gergely,L. Mooney, Y. Li,S.J. Oliver,W. Hueber,A.M. Wright

SLE, Sjögren’s and APS – clinical aspects (other than treatment)（2018）

Cited2Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn